Eupraxia Pharmaceuticals Inc. (EPRX) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -10.01M | -9.88M | -4.51M | -8.32M | -6M | -5.97M | -10.19M | -7.7M | -6.14M | -6.11M | -5.94M | -4.33M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -66.68% | -65.41% | 55.77% | -8.05% | 2.18% | 2.31% | -71.41% | -77.84% | -34.36% | -56.75% | -1.1% | -16.17% |
| Net Income | -12.45M | -16.95M | -6.37M | -8.75M | -6.77M | -7.53M | -5.99M | -6.06M | -6.16M | -10.86M | -4.9M | -9.5M |
| Depreciation & Amortization | 88.9K | 73.86K | 62.99K | 55.43K | 46.49K | 54.51K | 37.76K | 42.03K | 37.42K | 7.82K | 38.72K | 38.63K |
| Stock-Based Compensation | 0 | 0 | 446.11K | 1.12M | 1.49M | 1.03M | 507.25K | 1.47M | 213.13K | 320.1K | 358.88K | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.96M | 0 | 0 |
| Other Non-Cash Items | -404.43K | 7.24M | -347.41K | 735.58K | -68.29K | -91.38K | -4.28K | -304.38K | -480.46K | 6.37M | -1.8M | 4.14M |
| Working Capital Changes | 2.76M | -235.18K | 1.7M | -1.48M | -707.4K | 568.72K | -4.74M | -2.84M | 250.12K | 6.45K | 351.93K | 992.44K |
| Change in Receivables | 23.63K | -537.13K | -7.28K | 112.77K | -8.68K | -182.69K | 50.43K | 13.67K | 17.2K | -165 | -17.84K | 37.26K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.52M | 1.79M | 0 | 0 | 0 | 870.82K | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | -78.94M | -196.29K | -60.38K | -166.22K | -169.04K | -43.76K | -42.27K | 17.66K | -6.79K | -65.43K | -9.6K | -6.4K |
| Capital Expenditures | -322.42K | -196.29K | -60.38K | -166.22K | -169.04K | -44.31K | -42.27K | -10.85K | -6.79K | -65.43K | -9.6K | -6.4K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 558 | 0 | 28.51K | 0 | 0 | 0 | 0 |
| Cash from Financing | 67.63M | 1.47M | 73.9M | 239.78K | 429.92K | 31.73M | -4.6M | -4.52M | 23.17M | 7.89K | 16.29M | 4.67M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | -4.6M | -4.52M | -20.55K | -37.52K | -19.8K | -20.01K |
| Equity Issued (Net) | 67.63M | 1.47M | 73.89M | 0 | 0 | 31.71M | 0 | 0 | 22.85M | 47.92K | 15.89M | 4.67M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 6.79K | 239.78K | 429.92K | 25.86K | 0 | 0 | 337.2K | -2.51K | 421K | 16.55K |
| Net Change in Cash | -21.72M | -8.45M | 69.19M | -7.69M | -5.65M | 24.44M | -14.65M | -12.59M | 16.57M | -5.09M | 10.14M | 469.35K |
| Free Cash Flow | -10.33M | -10.07M | -4.57M | -8.48M | -6.17M | -6.02M | -10.23M | -7.71M | -6.14M | -6.16M | -5.95M | -4.33M |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | -67.34% | -67.45% | 55.37% | -10.05% | -0.47% | 2.38% | -71.84% | -77.83% | -34.27% | -55.52% | -0.4% | -11.39% |
| FCF per Share | -0.18 | -0.19 | -0.12 | -0.24 | -0.17 | -0.17 | -0.29 | -0.22 | -0.21 | -0.26 | -0.22 | -0.20 |
| FCF Conversion (FCF/Net Income) | 0.80x | 0.59x | 0.71x | 0.70x | 0.62x | 0.55x | 1.26x | 0.94x | 1.02x | 0.60x | 1.26x | 0.46x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 102 | 0 | 0 | 162.19K | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |